Holen Sie sich die Stockscreener-App
131.52
0.81%
-1.07
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BIIB?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$132.59
Offen:
$133.05
24-Stunden-Volumen:
976.95K
Relative Volume:
0.68
Marktkapitalisierung:
$19.27B
Einnahmen:
$9.82B
Nettoeinkommen (Verlust:
$1.48B
KGV:
12.98
EPS:
10.13
Netto-Cashflow:
$2.30B
1W Leistung:
+5.22%
1M Leistung:
+3.31%
6M Leistung:
-10.04%
1J Leistung:
-42.17%
1-Tages-Spanne:
$130.13
$133.05
1-Wochen-Bereich:
$121.05
$133.05
52-Wochen-Spanne:
$110.03
$219.44
Biogen Inc Stock (BIIB) Company Profile
Firmenname
Biogen Inc
Sektor
Telefon
(781) 464-2000
Adresse
225 BINNEY STREET, CAMBRIDGE, MA
Vergleichen Sie BIIB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
131.52 | 19.43B | 9.82B | 1.48B | 2.30B | 10.13 |
|
LLY
Lilly Eli Co
|
812.69 | 723.06B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
168.30 | 407.97B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
190.28 | 337.08B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
117.70 | 227.39B | 55.19B | 13.65B | 16.81B | 6.86 |
|
NVO
Novo Nordisk Adr
|
71.70 | 314.28B | 43.59B | 15.04B | 10.74B | 3.3766 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-21 | Fortgesetzt | Truist | Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-04-04 | Herabstufung | Argus | Buy → Hold |
| 2025-02-11 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-01-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-09 | Herabstufung | Jefferies | Buy → Hold |
| 2024-11-18 | Herabstufung | Needham | Buy → Hold |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-14 | Bestätigt | Needham | Buy |
| 2024-02-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-12-20 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-12-07 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-24 | Bestätigt | UBS | Buy |
| 2023-05-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-04-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | Hochstufung | Goldman | Neutral → Buy |
| 2022-10-13 | Hochstufung | Stifel | Hold → Buy |
| 2022-10-07 | Hochstufung | Argus | Hold → Buy |
| 2022-09-28 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | Hochstufung | Mizuho | Neutral → Buy |
| 2022-09-28 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | Herabstufung | Stifel | Buy → Hold |
| 2022-03-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | Bestätigt | Barclays | Equal Weight |
| 2022-02-04 | Bestätigt | BofA Securities | Neutral |
| 2022-02-04 | Bestätigt | Cowen | Outperform |
| 2022-02-04 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-04 | Bestätigt | Needham | Buy |
| 2022-02-04 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-04 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | Bestätigt | Robert W. Baird | Neutral |
| 2022-02-04 | Bestätigt | Wedbush | Neutral |
| 2022-02-04 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-02-04 | Bestätigt | Wolfe Research | Peer Perform |
| 2022-01-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-01-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-06-18 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | Bestätigt | Truist | Buy |
| 2021-06-11 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-08 | Hochstufung | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | Bestätigt | Barclays | Equal Weight |
| 2021-06-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2021-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-08 | Bestätigt | Jefferies | Buy |
| 2021-06-08 | Bestätigt | Morgan Stanley | Overweight |
| 2021-06-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | Bestätigt | Stifel | Buy |
| 2021-06-08 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-06-07 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-06-07 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-01-29 | Hochstufung | Stifel | Hold → Buy |
| 2020-11-10 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-11-09 | Herabstufung | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-11-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-11-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-04 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-11-04 | Hochstufung | Jefferies | Hold → Buy |
| 2020-11-04 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-07-27 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-06-22 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | Herabstufung | Citigroup | Neutral → Sell |
| 2020-04-23 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-27 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | Herabstufung | Robert W. Baird | Neutral → Underperform |
Alle ansehen
Biogen Inc Aktie (BIIB) Neueste Nachrichten
Is Biogen Inc. a good long term investmentFree Stock Market Knowledge Sharing - PrintWeekIndia
Biogen is the latest entrant in NC’s corporate investment surge - Carolina Journal
KalVista, Biogen, Ionis get EU positive opinions for key drugs (KALV:NASDAQ) - Seeking Alpha
What institutions are buying Biogen Inc. stock nowFree Stock Market Trend Analysis - jammulinksnews.com
Biogen Inc. Announces Positive Opinion from EMA for ZURZUVAE® as First Marketing Authorization for Postpartum Depression Treatment in the EU - Quiver Quantitative
Biogen Inc. - Via Ritzau
ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression - Yahoo Finance
Zacks Research Has Negative Outlook for Biogen Q2 Earnings - MarketBeat
Truist Financial Begins Coverage on Biogen (NASDAQ:BIIB) - MarketBeat
What analysts say about Biogen Inc. stockExponentially increasing returns - Autocar Professional
Genentech Seeks Win After $122M Biogen Royalties Mistrial - Law360
Biogen’s Felzartamab Trial: A Potential Game-Changer for Kidney Transplant Recipients - TipRanks
Biogen, Zydus Settle Patent Suit Over Copies of MS Drug Vumerity - Bloomberg Law News
Biogen’s Felzartamab Study: A Potential Game-Changer for IgA Nephropathy - TipRanks
Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Universal Beteiligungs und Servicegesellschaft mbH Has $21.55 Million Stock Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Victory Capital Management Inc. Purchases 5,723 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Inc. Stock Analysis and ForecastExceptional gains - Autocar Professional
Biogen to invest $2 billion in RTP, open new factory in 2025 - WRAL.com
(BIIB) On The My Stocks Page - news.stocktradersdaily.com
Biogen Inc. (BIIB) Partners with Stoke Therapeutics to Tackle Dravet Syndrome - MSN
Rep. Robert Bresnahan, Jr. Buys Biogen Inc. (NASDAQ:BIIB) Shares - MarketBeat
How the Recombinant Dna Technology Market Will Evolve by 2032 - openPR.com
KLP Kapitalforvaltning AS Purchases 63,700 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Envestnet Asset Management Inc. Increases Stock Holdings in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Will Major North Carolina Expansion Change Biogen's (BIIB) Narrative? - simplywall.st
What drives Biogen Inc. stock pricePowerful growth strategies - jammulinksnews.com
Beacon Investment Advisory Services Inc. Sells 3,529 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
FDA Names Biotech Veteran George Tidmarsh To Lead Drug Evaluation Division - Benzinga
Biogen, one of the largest employers in RTP, plans $2B investment in the Triangle - Axios
How Will AbbVie's Neuroscience Franchise Perform in Q2 Earnings? - The Globe and Mail
Allianz Asset Management GmbH Increases Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Los Angeles Capital Management LLC Takes $5.93 Million Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Spinal Muscular Atrophy Treatment Market Growth Accelerated - openPR.com
Biogen: Hold Rating Amid Stagnant Growth and Uncertain Prospects - TipRanks
Biogen to invest additional $2B in North Carolina’s Research Triangle Park - MSN
Biogen to invest further $2bn in North Carolina’s Research Triangle Park - Yahoo Finance
Iovance Biotherapeutics shares rise 2.41% premarket after Biogen's $2 billion investment in North Carolina manufacturing. - AInvest
AustralianSuper Pty Ltd Buys New Position in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen investing $2B to expand operations in RTP - ABC11
Biogen's Alzheimer's Innovation Pipeline: Lecanemab and BIIB080 as Catalysts for Long-Term Growth - AInvest
Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi - yahoo.co
Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025 - Biogen
Biogen Breakthrough: 48-Month LEQEMBI Results Plus Game-Changing Subcutaneous Alzheimer's Treatment Option - Stock Titan
Edgestream Partners L.P. Sells 3,285 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen to invest $2 billion in RTP facility - CBS 17
Biogen Inc. Invests $2B In North Carolina Expansion - Business Facilities
Biogen Inc. Announces $2 Billion Expansion in North Carolina's Research Triangle Park Amid U.S. Manufacturing Push - Hoodline
Friedreich's Ataxia Market Is Expanding Due To Advancing - openPR.com
Biogen (BIIB) Stock Trades Down, Here Is Why - Yahoo Finance
Biogen Bets Big On $2 Billion Expansion To Boost US Drug ManufacturingBiogen (NASDAQ:BIIB) - Benzinga
Finanzdaten der Biogen Inc-Aktie (BIIB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
2.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):